P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

• A. M. Zeidan,
• D. A. Pollyea,
• U. Borate,
• A. Vasconcelos,
• R. Potluri,
• D. Rotter,
• Z. Kiendrebeogo,
• L. Gaugler,
• G. Bonifacio,
• T. Prebet,
• C. Chen

Affiliations

A. M. Zeidan

1 Yale University School of Medicine, New Haven, CT

D. A. Pollyea

2 University of Colorado School of Medicine, Aurora, CO

U. Borate

3 Oregon Health & Science University, Portland, OR

A. Vasconcelos

4 Bristol Myers Squibb, Princeton, NJ

R. Potluri

5 SmartAnalyst Inc., New York, NY, United States of America

D. Rotter

5 SmartAnalyst Inc., New York, NY, United States of America

Z. Kiendrebeogo

5 SmartAnalyst Inc., New York, NY, United States of America

L. Gaugler

4 Bristol Myers Squibb, Princeton, NJ

G. Bonifacio

4 Bristol Myers Squibb, Princeton, NJ

T. Prebet

4 Bristol Myers Squibb, Princeton, NJ

C. Chen

4 Bristol Myers Squibb, Princeton, NJ